Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B4GALT1 | P15291 | 1/20 | 0.62 |
| ▸ | GBA1 | P04062 | 5/20 | 0.60 |
| ▸ | GLB1 | P16278 | 4/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034127 | 1.00 | B4GALT1 (0.62) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1034124 | 1.00 | B4GALT1 (0.62) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1034677 | 1.00 | B4GALT1 (0.62) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1077400 | 0.93 | GBA1 (0.65) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1035610 | 0.86 | B4GALT1 (0.53) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1035609 | 0.86 | B4GALT1 (0.53) | B4GALT1GBA1GLB1HDAC4HDAC10 | |
| SCHEMBL1031119 | 0.84 | GBA1 (0.54) | B4GALT1GBA1GLB1 | |
| SCHEMBL1031118 | 0.84 | GBA1 (0.54) | B4GALT1GBA1GLB1 | |
| SCHEMBL572629 | 0.78 | HDAC4 (0.65) | GBA1GLB1HDAC4HDAC10HDAC6 | |
| SCHEMBL12599998 | 0.78 | GBA1 (0.59) | B4GALT1GBA1GLB1HDAC4HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112184-A1 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | NICOTRA, FRANCESCO (IT) | 2011-05-12 | — | — | US | claimed |
| EP-2276773-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | La Ferla, Barbara (IT) | 2011-01-26 | — | — | EP | claimed |
| WO-2009135673-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC | LA FERLA BARBARA (IT) | 2009-11-12 | — | — | WO | claimed |
| US-20110112184-A1 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | NICOTRA, FRANCESCO (IT) | 2011-05-12 | — | — | US | disclosed |
| EP-2276773-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | La Ferla, Barbara (IT) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009135673-A2 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC | LA FERLA BARBARA (IT) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112184-A1 | COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION | C9, CCR10, CA9 | B4GALT1 162/4885GBA1 272/4885GLB1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.